Voyager Therapeutics
healthcare & pharma · United States · Accounts: Voyager Therapeutics, Inc.
- Dividends paid 2025
- Not available
From the stored figures
- Revenue went from $14m in 2016 to $40m in 2025 (+184%).
- Reported workforce went from 77 (2016) to 141 (2025).
Cuts against payouts
Jobs cut each year (tracker events) beside dividends and buybacks paid that year
Jobs: confirmed figures, else the stated "up to"; estimates and rumours not counted. Figures from SEC EDGAR XBRL, SEC annual filing. Original reporting currency. "Not available" means no stored figure; nothing is estimated.
Revenue and profit
Revenue as bars; pre-tax and net profit to shareholders as lines
Figures from SEC EDGAR XBRL, SEC annual filing. Original reporting currency. "Not available" means no stored figure; nothing is estimated.
Dividends and buybacks
Cash paid to shareholders each year; buybacks shown separately
Figures from SEC EDGAR XBRL, SEC annual filing. Original reporting currency. "Not available" means no stored figure; nothing is estimated.
Workforce
Year-end headcount the company reports; triangles mark job-cut events
Headcount from annual filings. Cuts from the tracker's events.
Revenue and profit per employee
Each year's stored figure divided by that year's reported headcount
Figures from SEC EDGAR XBRL, SEC annual filing. Original reporting currency. "Not available" means no stored figure; nothing is estimated.
Every figure and its source
Original currency. Tap a figure to open its filing.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
4 of 10 years complete · checked 28 Oct 2026 · SEC CIK 1640266
Gaps (6)
- 2016: cash dividends paid — not tagged in the filing
- 2017: cash dividends paid — not tagged in the filing
- 2022: cash dividends paid — not tagged in the filing
- 2023: cash dividends paid — not tagged in the filing
- 2024: cash dividends paid — not tagged in the filing
- 2025: cash dividends paid — not tagged in the filing
Queued: company annual-report search for 2016, 2017, 2022, 2023, 2024, 2025, from 29 Oct 2026.